Mobilization regimens prior to stem-cell collection in patients with lymphoma: how to choose?
Shimoni
Avichai
A
The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel. ashimoni@sheba.health.gov.il
Hardan
Izhar
I
D018952:Antigens, CD34 / Q000096:biosynthesis; D001854:Bone Marrow Cells / Q000166:cytology; D054377:Chemokine CXCL12 / Q000378:metabolism; D005047:Etoposide / Q000494:pharmacology; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D008223:Lymphoma / Q000097:blood* / Q000628:therapy*; D012008:Recurrence; D012306:Risk; D033581:Stem Cell Transplantation / Q000379:methods*; D016896:Treatment Outcome
D018952:Antigens, CD34; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide